Read by QxMD icon Read

radioembolization hcc

Rehan Ali, Yihe Yang, Mark Antkowiak, Ahmed Gabr, Ronald Mora, Nadine Abouchaleh, Ali Al Asadi, Laura Kulik, Daniel Ganger, Michael Abecassis, Nitin Kataraya, Mary Mulcahy, Al Benson, Devalingam Mahalingam, Bartley Thornburg, Samdeep Mouli, Robert J Lewandowski, Riad Salem, Ahsun Riaz
AIMS: To investigate laboratory parameters as predictors of overall survival (OS) for hepatocellular carcinoma (HCC) treated with radioembolization and develop/validate a scoring system. METHODS: With IRB approval, we included all patients with baseline alpha-fetoprotein (AFP) > 100 ng/dL from our prospectively acquired HCC radioembolization database. Neutrophil-lymphocyte ratio, albumin-bilirubin (ALBI), and AFP were measured at baseline and at 1-, 3-, and 6-month post-radioembolization Landmarks...
March 1, 2019: Cardiovascular and Interventional Radiology
Lisa B Liu, Mario A Cedillo, Vivian Bishay, Mona Ranade, Rahul S Patel, Edward Kim, Scott F Nowakowski, Robert A Lookstein, Aaron M Fischman
PURPOSE: To determine patient preference for transradial access (TRA) or transfemoral access (TFA) after experiencing both. MATERIALS AND METHODS: A randomized controlled crossover trial was conducted at a single institution. Thirty patients with hepatocellular carcinoma undergoing mapping and transarterial radioembolization (TARE) were enrolled to experience 1 TRA and 1 TFA procedure each, with randomization of which access approach was experienced first. Surveys assessing pain and quality of life (QOL) were administered after each procedure...
March 2019: Journal of Vascular and Interventional Radiology: JVIR
Matthew D Li, Katrina F Chu, Allegra DePietro, Vincent Wu, Eric Wehrenberg-Klee, Omar Zurkiya, Raymond W Liu, Suvranu Ganguli
PURPOSE: To evaluate the feasibility of a same-day yttrium-90 (90 Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases. MATERIALS AND METHODS: All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC...
March 2019: Journal of Vascular and Interventional Radiology: JVIR
José Carlos De La Vega, Pedro Luis Esquinas, Cristina Rodríguez-Rodríguez, Mehrdad Bokharaei, Igor Moskalev, David Liu, Katayoun Saatchi, Urs O Häfeli
A common form of treatment for patients with hepatocellular carcinoma (HCC) is transarterial radioembolization (TARE) with non-degradable glass or resin microspheres (MS) labeled with 90 Y (90 Y-MS). To further simplify the dosimetry calculations in the clinical setting, to have more control over the particle size and to change the permanent embolization to a temporary one, we developed uniformly-sized, biodegradable 188 Re-labeled MS (188 Re-MS) as a new and easily imageable TARE agent. Methods: MS made of poly( L -lactic acid) were produced in a flow focusing microchip...
2019: Theranostics
Sungwon Kim, Do Young Kim, Chansik An, Kyunghwa Han, Jong Yun Won, Gyoung Min Kim, Myeong Jin Kim, Jin Young Choi
OBJECTIVE: To identify an imaging predictor for the assessment of early treatment response to yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC), using a quantitative assessment of dynamic computed tomography (CT) images. MATERIALS AND METHODS: Dynamic contrast-enhanced CT was obtained pre- and 4 weeks post-TARE in 44 patients (34 men, 10 women; mean age, 60 years) with HCC. Computer software was developed for measuring the percentage increase in the combined delayed-enhancing area and necrotic area (pD + N) and the percentage increase in the necrotic area (pNI) in the tumor-containing segments pre- and post-TARE...
March 2019: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
Pyeong Hwa Kim, Sang Hyun Choi, Jin Hyoung Kim, Seong Ho Park
OBJECTIVE: To compare the safety and efficacy of radioembolization with that of sorafenib for the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). MATERIALS AND METHODS: MEDLINE, EMBASE, and Cochrane databases were searched for studies reporting outcomes in patients with HCC and PVTT treated with radioembolization or sorafenib. Meta-analyses of cumulative overall survival (OS) and Kaplan-Meier survival rates according to the time to progression (TTP) and incidence of adverse events (AEs) were performed...
March 2019: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
Heather M McGee, Michael J King, Umut Özbek, Ashley Olson, Edward Kim, Aaron M Fischman, Myron Schwartz, Kenneth E Rosenzweig, Michael Buckstein
OBJECTIVES: Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) have poor outcomes with systemic therapy such as sorafenib. Both external beam radiation therapy (EBRT) and transarterial radioembolization (TARE) have been utilized for this patient population. We sought to compare outcomes using dual modality radiation (EBRT+TARE) versus EBRT alone in patients with HCC and GVI. MATERIALS AND METHODS: Between 2011 and 2017, 45 patients with HCC and GVI were treated with EBRT±TARE at our institution...
February 6, 2019: American Journal of Clinical Oncology
Kostas Delaunay, Julien Edeline, Yan Rolland, Nicolas Lepareur, Sophie Laffont, Xavier Palard, Christelle Bouvry, Samuel Le Sourd, Marc Pracht, Valérie Ardisson, Nicolas Noiret, Éric Bellissant, Etienne Garin
PURPOSE: This study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188 Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study. METHODS: Results of the first six patients included are reported. Analysis of the 188 Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration...
February 4, 2019: European Journal of Nuclear Medicine and Molecular Imaging
Amit G Singal, Nicole E Rich, Neil Mehta, Andrea Branch, Anjana Pillai, Maarouf Hoteit, Michael Volk, Mobolaji Odewole, Steven Scaglione, Jennifer Guy, Adnan Said, Jordan J Feld, Binu V John, Catherine Frenette, Parvez Mantry, Amol S Rangnekar, Omobonike Oloruntoba, Michael Leise, Janice H Jou, Kalyan Ram Bhamidimarri, Laura Kulik, Tram Tran, Hrishikesh Samant, Renumathy Dhanasekaran, Andres Duarte-Rojo, Reena Salgia, Sheila Eswaran, Prasun Jalal, Avegail Flores, Sanjaya K Satapathy, Robert Wong, Annsa Huang, Suresh Misra, Myron Schwartz, Robert Mitrani, Sasank Nakka, Wassim Noureddine, Chanda Ho, Venkata R Konjeti, Alexander Dao, Kevin Nelson, Kelly Delarosa, Usman Rahim, Meher Mavuram, Jesse J Xie, Caitlin C Murphy, Neehar D Parikh
BACKGROUND & AIMS: There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort. METHODS: We conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, trans-arterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 health systems throughout the United States and Canada...
January 17, 2019: Gastroenterology
Isabel Schobert, Julius Chapiro, Nariman Nezami, Charlie Alexander Hamm, Bernhard Gebauer, Ming De Lin, Jeffrey Pollak, Lawrence Saperstein, Todd Schlachter, Lynn Jeanette Savic
To identify baseline imaging features in patients with liver cancer that correlate with Yttrium-90 (90 Y) distribution on post-procedural single photon emission computed tomography (SPECT) and predict tumor response to transarterial radioembolization (TARE). Methods: This retrospective study was approved by the institutional review board and included 38 patients with hepatocellular carcinoma (HCC) ( n = 23, 18/23 males, mean age 62.39±8.62 years, 34 dominant tumors) and non-HCC hepatic malignancies ( n = 15, 9/15 males, mean age 61...
January 17, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Carlo Sposito, Vincenzo Mazzaferro
No abstract text is available yet for this article.
December 2018: Hepatobiliary Surgery and Nutrition
Aman Saini, Alex Wallace, Sadeer Alzubaidi, M Grace Knuttinen, Sailendra Naidu, Rahul Sheth, Hassan Albadawi, Rahmi Oklu
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. Following the development of glass and resin Y90 microspheres in the early 1990s, Y90 radioembolization has been shown to be a safe and efficacious treatment for patients with HCC across Barcelona Clinic Liver Cancer (BCLC) stages...
January 7, 2019: Journal of Clinical Medicine
Christoph G Radosa, Julia C Radosa, Sabine Grosche-Schlee, Klaus Zöphel, Verena Plodeck, Jens P Kühn, Jörg Kotzerke, Ralf-Thorsten Hoffmann
PURPOSE: To investigate clinical feasibility, technical success and toxicity of 166 Ho-radioembolization (166 Ho-RE) as new approach for treatment of hepatocellular carcinomas (HCC) and to assess postinterventional calculation of exact dosimetry through quantitative analysis of MR images. MATERIALS AND METHODS: From March 2017 to April 2018, nine patients suffering from HCC were treated with 166 Ho-RE. To calculate mean doses on healthy liver/tumor tissue, MR was performed within the first day after treatment...
January 2, 2019: Cardiovascular and Interventional Radiology
Thomas Couri, Anjana Pillai
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC, many molecular pathways are implicated in HCC carcinogenesis, including the TERT promoter mutation, Wnt/β-catenin, P53, Akt/mTOR, vascular endothelial growth factor receptor (VEGFR), and endothelial growth factor receptor (EGFR)/RAS/MAPK pathways. While the most widely used staging and treatment algorithm for HCC-the Barcelona Clinic Liver Cancer (BCLC) system-does not recommend systemic molecular therapy for early HCC, a variety of treatment options are available depending upon the stage of HCC at diagnosis...
January 1, 2019: Hepatology International
P d'Abadie, M Hesse, F Jamar, R Lhommel, S Walrand
Clinical studies reported a twofold ratio between the efficacies per Gy of resin versus glass spheres. Our aim is to investigate whether this difference could result from the different degrees of heterogeneity in sphere distribution between the two medical devices. The 90 Y TOF-PET based equivalent uniform doses (EUD) was used for this purpose. 58 consecutive HCC radioembolizations were retrospectively analyzed. Absorbed doses D and Jones-Hoban EUD in lesions were computed. Radioembolization efficacy was assessed using Kaplan-Meier survival curves...
December 12, 2018: Physics in Medicine and Biology
Pedro L Esquinas, Ajit Shinto, Koramadai K Kamaleshwaran, Jephy Joseph, Anna Celler
BACKGROUND: Rhenium-188-labelled-Lipiodol radioembolization is a safe and cost-effective treatment for primary liver cancer. In order to determine correlations between treatment doses and patient response to therapy, accurate patient-specific dosimetry is required. Up to date, the reported dosimetry of 188 Re-Lipiodol has been based on whole-body (WB) planar imaging only, which has limited quantitative accuracy. The aim of the present study is to determine the in vivo pharmacokinetics, bio-distribution, and organ-level dosimetry of 188 Re-AHDD-Lipiodol radioembolization using a combination of post-treatment planar and quantitative SPECT/CT images...
December 7, 2018: EJNMMI Physics
Homan Mohammadi, Yazan Abuodeh, William Jin, Jessica Frakes, Mark Friedman, Benjamin Biebel, Junsung Choi, Ghassan El-Haddad, Bela Kis, Jennifer Sweeney, Sarah Hoffe
Background: The Child-Pugh (CP) class is a commonly used scoring system to measure liver function in patients with hepatocellular carcinoma (HCC). We correlate the Albumin-Bilirubin (ALBI) grading system and CP to overall survival in our HCC patients receiving radioembolization. Methods: We retrospectively evaluated patients who received radioembolization for HCC between the years 2009-2014. We evaluated the albumin and bilirubin levels in our patients prior to receiving their first (n=124) radioembolization...
October 2018: Journal of Gastrointestinal Oncology
Andrea Casadei Gardini, Emiliano Tamburini, Mercedes Iñarrairaegui, Giovanni Luca Frassineti, Bruno Sangro
Purpose: This study aimed to compare clinically relevant outcomes following transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) using only prospective randomized clinical trials as a source of information. Materials and methods: A meta-analysis was performed to compare the efficacy of TARE and TACE in treating patients with unresectable HCC. Only prospective randomized trials were included in the quantitative analysis...
2018: OncoTargets and Therapy
Remco Bastiaannet, S Cheenu Kappadath, Britt Kunnen, Arthur J A T Braat, Marnix G E H Lam, Hugo W A M de Jong
Radioembolization is an established treatment for chemoresistant and unresectable liver cancers. Currently, treatment planning is often based on semi-empirical methods, which yield acceptable toxicity profiles and have enabled the large-scale application in a palliative setting. However, recently, five large randomized controlled trials using resin microspheres failed to demonstrate a significant improvement in either progression-free survival or overall survival in both hepatocellular carcinoma and metastatic colorectal cancer...
November 2, 2018: EJNMMI Physics
T Kirchner, S Marquardt, T Werncke, M M Kirstein, T Brunkhorst, F Wacker, A Vogel, Thomas Rodt
PURPOSE: The purpose of this study was to compare quality of life (QoL) after two different transarterial therapies [transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)] for patients with unresectable hepatocellular carcinoma (HCC) to assess tumor therapy in palliative situation additional to traditional aims like survival or image response. MATERIAL AND METHODS: QoL was evaluated with two validated questionnaires (EORTC QLQ-30 and EORTC HCC18) before and 14d after treatment in 94 initial therapies (TACE n = 67; TARE n = 27)...
October 11, 2018: Abdominal Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"